Breaking News
Sort by:
Top Post
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has approved Dupixent (dupilumab) […]
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) expanded the marketing authorization […]
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 3 trial jointly run with the […]
Libtayo ® (Cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted […]
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Read more
- Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Read more
- Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Read more
- Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Read more
- Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Read more